Effective and selective targeting of leukemia cells using a TORC1/2 kinase inhibitor

Targeting the mammalian target of rapamycin (mTOR) protein is a promising strategy for cancer therapy. The mTOR kinase functions in two complexes, TORC1 (target of rapamycin complex-1) and TORC2 (target of rapamycin complex-2); however, neither of these complexes is fully inhibited by the allosteric inhibitor rapamycin or its analogs. We compared rapamycin with PP242, an inhibitor of the active site of mTOR in both TORC1 and TORC2 (hereafter referred to as TORC1/2), in models of acute leukemia harboring the Philadelphia chromosome (Ph) translocation.

Read the full abstract on PubMed →

Janes, M. R., et al. (2010). Effective and selective targeting of leukemia cells using a TORC1/2 kinase inhibitor. Nature medicine. https://doi.org/10.1038/nm.2091

@article{JAN2010,
  author       = {Janes, M. R. and Fruman, D. A. and others},
  title        = {{Effective and selective targeting of leukemia cells using a TORC1/2 kinase inhibitor}},
  journal      = {Nature medicine},
  year         = {2010},
  doi          = {10.1038/nm.2091},
  note         = {PMID: 20072130},
}

Cite this Atlas record

The record is the Atlas's own work — the evidence label, the extracted findings and the links. It is cited as part of the dataset, not as the paper.

Barton, O. (2026). Oliver's mTOR Atlas (record JAN2010) [Data set]. https://mtor-atlas.org/study/JAN2010/ · Dataset DOI 10.5281/zenodo.22059963

@misc{atlas_JAN2010,
  author       = {Barton, Oliver},
  title        = {{Oliver's mTOR Atlas}, record JAN2010},
  howpublished = {Data set},
  year         = {2026},
  url          = {https://mtor-atlas.org/study/JAN2010/},
  doi          = {10.5281/zenodo.22059963}
}